On March 10, 2022 Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chief executive officer, Rami Elghandour and chief medical officer, Chris Heery, M.D.,will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022, at 4:50 p.m. E.T.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investor section. A replay of the webcast will be archived and available for 30 days following the event.

On March 10, 2022 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, reported that company management will present its corporate highlights at the upcoming Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 2:00 p.m. ET (Press release, Gamida Cell, MAR 10, 2022, View Source [SID1234609930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available on the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

On March 10, 2022 Puma Biotechnology, Inc. (the Company) (Nasdaq: PBYI), a biopharmaceutical company, reported that it has entered into a securities purchase agreement with Alan H Auerbach, the Company’s Chief Executive Officer, President and Chairman of the Board, as well as a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportunities in the global healthcare sector, in connection with the sale in a private placement of 3,584,228 shares of common stock at a purchase price of $2.79 per share, which was the closing price of the common stock on the Nasdaq Global Select Market on the date of the securities purchase agreement (Press release, Puma Biotechnology, MAR 10, 2022, View Source [SID1234609929]). Gross proceeds to the Company will be approximately $10 million before deducting any offering expenses. The Company plans to use the net proceeds from the private placement primarily for general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The private placement is expected to close on March 10, 2022, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (SEC).

The shares of common stock being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 10, 2022 Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, reported that it will participate in the following upcoming industry events and conferences (Press release, Perimeter Medical Imaging AI, MAR 10, 2022, View Source [SID1234609928]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SSO 2022 – Society of Surgical Oncology’s International Conference on Surgical Cancer Care in Dallas, TX from March 9-12, 2022.
Spotlight Presentation: "A New Paradigm for Intraoperative Margin Visualization with OCT + Future AI" on Friday, March 11, 2022 at 12-12:15 pm CT by Dr. Beth Dupree and Dr. Amelia Tower. Learn more.
NCoBC 2022 – National Consortium of Breast Centers’ 31st Interdisciplinary Breast Center Conference in Las Vegas, NV from March 11-16, 2022. Learn more.
ASBrS 2022 – 23rd Annual Meeting of the American Society of Breast Surgeons in Las Vegas, NV from April 6-10, 2022.
Breakfast Symposium: "OCT + Future AI: Changing the Paradigm for Intraoperative Margin Visualization" on Friday, April 8, 2022 from 6:15-7:45 am PT by Dr. Richard Fine (Moderator), Dr. Amelia Tower, and Dr. Maryam Elmi. Learn more.
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the "Investors" section of Perimeter’s website at View Source When available, webcasts will be posted for replay following the event.

On March 10, 2022 RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, reported the close of an $80 million equity financing (Press release, RefleXion Medical, MAR 10, 2022, View Source [SID1234609927]). In addition to participation from RefleXion’s existing investors, the company also welcomes investments from Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"RefleXion’s breakthrough technology holds the potential to expand the reach of radiotherapy to late-stage cancers where five-year survival is less than 31%," said Tara Butler, M.D., senior managing director of Ascension Ventures. "We believe wholeheartedly in their goals of improving outcomes for these patients, and in prioritizing the availability of BgRT at community hospitals thereby enabling patients to receive their cancer treatment without traveling long distances."

Existing RefleXion investors that participated in the round include TPG’s The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Partners, Venrock, and global pharmaceutical leaders, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc.

BgRT is the first and only technology designed to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors. RefleXion’s BgRT recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for use in lung tumors because of its potential to detect and then immediately treat moving targets. The company aims to one day scale BgRT to treat all visible cancer sites to create a new treatment option for patients with metastatic disease.

"The steadfast belief in RefleXion’s vision by our investor syndicate gives us the runway to drive hard and fast toward developing our platform for indications where radiotherapy was previously considered palliative only," said Todd Powell, president and CEO of RefleXion. "In just under a year, we have gained experience with image-guided radiotherapy by delivering nearly 2,000 patient treatments, successfully completed our feasibility study, secured an additional key radiopharmaceutical agreement, and expanded our commercial footprint."

"These important milestones lay the foundation for our future introduction of biology-guided radiotherapy," continued Powell.